Merck Animal Health has launched Engemycin® DD in Canada, giving dairy farmers a new antibiotic option for herd health. The short-acting oxytetracycline is approved for use in cattle, swine, and sheep.
The product arrives at a time when Canadian farmers have faced fewer broad-spectrum antibiotic choices. Several products were pulled from the market in recent years, creating pressure on veterinarians and producers. Engemycin® DD helps fill that gap with a treatment that is both effective and manageable in dairy herds. Its short-acting formula means producers can treat sick animals without long milk withdrawal times.
Engemycin® DD is classified as a Category III antimicrobial. These drugs are considered less critical to human medicine compared to Category I, which are highly restricted in livestock. By expanding options in lower-risk categories, the product supports responsible antibiotic use while protecting animal health.
“Engemycin® DD gives producers a viable option where they have had limited choices for broad-spectrum antibiotics,” said Dr. Ray Reynen, DVM, Veterinary Services, Cattle at Merck Animal Health.
The launch has also been welcomed by industry leaders. David Wiens, President of Dairy Farmers of Canada, said, “Increasing the diversity of veterinary health care tools available in Canada is essential to positive health outcomes for animals and helping farmers play their part in reducing antimicrobial resistance.”
Regulators recognized the need for more treatment options. Merck Animal Health filed its updated dossier in early 2024, and the Veterinary Drugs Directorate granted a priority review. Engemycin® DD received market authorization in February 2025 and is now available through veterinarians across Canada.
